Novartis Korea Hit With Fine, Product Suspensions Over Illegal ‘Rebates’
Executive Summary
South Korea has confirmed administrative measures including a fine against Novartis Korea for illegal rebate payments following official probes last year.
You may also be interested in...
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.
Dong-A Faces Price Hit As Korea Ups Fight Against Illegal Rebates
In its ongoing clamp down against illegal rebate activities in the domestic pharmaceutical industry, South Korea cuts prices of Dong-A ST’s drugs. This follows recent punitive measures against Novartis' Korean subsidiary.